arsenic trioxide has been researched along with HPV Infection in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhtar, A; Bell, C; Ghali, L; Wang, SX; Wen, X | 1 |
| Du, S; Gao, P; Li, Z; Liu, K; Zheng, J | 1 |
| Gao, P; Wang, H; Zheng, J | 1 |
| Bandi, S; Dogra, S; Gupta, S; Viswanathan, P | 1 |
| Duru, N; Guo, Q; He, G; Kong, X; Li, JJ; Sui, L; Wan, B; Wang, L; Wang, Q; Wu, X; Yu, L; Zhang, P; Zhou, Y | 1 |
| Ghali, L; Iles, RK; Li, D; Liu, S; Wen, X; Zhang, Y | 1 |
6 other study(ies) available for arsenic trioxide and HPV Infection
| Article | Year |
|---|---|
Effective Delivery of Arsenic Trioxide to HPV-Positive Cervical Cancer Cells Using Optimised Liposomes: A Size and Charge Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Delivery Systems; Female; Humans; Liposomes; Oxides; Papillomavirus Infections; Particle Size; Static Electricity; Uterine Cervical Neoplasms | 2018 |
Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Middle Aged; Papillomaviridae; Papillomavirus Infections; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Repressor Proteins; Retinoblastoma Protein; Transcription Factor AP-1; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2014 |
Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Proliferation; Cell Transformation, Viral; Cisplatin; Comet Assay; DNA Breaks, Double-Stranded; Drug Synergism; Histones; Human papillomavirus 16; Humans; Kidney Neoplasms; Kidney Tubules; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Promoter Regions, Genetic; Repressor Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA Primers; Female; HeLa Cells; Human papillomavirus 16; Humans; Oxides; Papillomavirus Infections; Polymerase Chain Reaction; RNA, Messenger; Uterine Cervical Neoplasms; YY1 Transcription Factor | 2011 |
Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus Infections; Repressor Proteins; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2012 |